Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial | Zendy

Larry B. Goldstein | Zendy; Pierre Amarenco | Zendy; Justin A. Zivin | Zendy; Michael Messig | Zendy; Irfan Altafullah | Zendy; Alfred Callahan | Zendy; Michael G. Hennerici | Zendy; Mary Joan MacLeod | Zendy; Henrik Sillesen | Zendy; Richard M. Zweifler | Zendy; K. Michael | Zendy; Angela Welch | Zendy

Open Access

Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial

Author(s) -

Larry B. Goldstein,

Pierre Amarenco,

Justin A. Zivin,

Michael Messig,

Irfan Altafullah,

Alfred Callahan,

Michael G. Hennerici,

Mary Joan MacLeod,

Henrik Sillesen,

Richard M. Zweifler,

K. Michael,

Angela Welch

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.557330

Subject(s) - medicine , modified rankin scale , stroke (engine) , atorvastatin , randomized controlled trial , placebo , physical therapy , ischemic stroke , cardiology , ischemia , mechanical engineering , alternative medicine , pathology , engineering

Laboratory experiments suggest statins reduce stroke severity and improve outcomes. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was a placebo-controlled, randomized trial designed to determine whether treatment with atorvastatin reduces strokes in subjects with recent stroke or transient ischemic attack (n=4731). We analyzed SPARCL trial data to determine whether treatment favorably shifts the distribution of severities of ischemic cerebrovascular outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research